Europe's #1 branded frozen roll-up — Birds Eye, iglo, Findus, Ledo across ~16 countries

• Shelf-space moat. ~17-18% share of Europe's savory frozen aisle; $3.57B FY25 revenue at 27.1% gross margin (lowest in peer set).
• Cash engine. $297M FCF in FY25 on light ~3% capex; per-share math driven by 18% float shrink since 2021 — 172M to 142M shares.
• Slow-growth, levered. Category grows ~1%, organic revenue -1.9% in FY25 (third straight negative year); $2.7B term loans, net debt/EBITDA ~4x.

Worst earnings year since 2021 — net income fell 32% while net debt re-expanded $466M

Revenue down 2.2% in EUR to €3.03B, gross margin off ~250 bps, interest expense nearly doubled to $212M on the Nov-25 refi — buybacks above FCF are being debt-funded and cannot continue at this pace.

Grade B — founder-aligned Jarden playbook, but $4M/yr advisory fee and an untested new CEO

• Founders still in. Franklin (7.3%) and Gottesman (7.1%) own ~14% a decade after the 2014 SPAC; insiders hold 18.4%; Franklin bought 500K shares for $5.1M at $10.46 on Mar 12 2026.
• New CEO, no category. Dominic Brisby (ex-Flora Food, ex-Imperial Brands) started Jan 1 2026 — zero frozen-food experience, zero Nomad shares at year-end, 'sizable' open-market buy promised but not yet disclosed.
• Buyback discipline works. 18% float shrink in 4 years pushed Franklin's stake from 6.3% to 7.3% without a single purchase; aggregate exec pay ~€10M is the lowest ratio in the peer set.
• Governance tax. $4M/yr advisory fee to Mariposa & TOMS family offices; Chubb/APi related-party spend jumped 6x to €4.7M; only 3 of 10 directors genuinely independent of the Franklin network; BVI domicile, FPI status.

A decade of roll-up compounding, then 2025 broke — and the founding CEO left

2014-2024 — The roll-up era. Franklin/Gottesman SPAC buys Iglo (2015, €2.6B), Findus (2016), Goodfella's & Aunt Bessie's (2018), Fortenova's Ledo/Frikom (2021, €642M). Nine consecutive years of record sales and Adjusted EBITDA through FY24. Management called itself a 'growth-advantaged food company.'

2025-now — The transition. Last deal closed Sep 2021. Organic revenue flipped negative (-1.9% FY25), margins compressed 210 bps, guidance cut three times in one year each blamed on a different cause. October 2025 the board replaces Descheemaeker with outsider Brisby, who immediately labels 2026 'a transition year' and halves the medium-term EBITDA growth target from 5-7% to 1-3%.

What the internet knows that the filings don't say

• Deutsche Bank downgrade. Steve Powers cut NOMD from Buy to Hold on Mar 30 2026, price target $15 to $10; Barclays trimmed $13 to $12 on Apr 15; consensus target now $12.50 vs Morningstar Quant outlier at $37.92.
• Chairman conviction buy. Martin Franklin purchased 500,000 shares for $5.1M at up to $10.46 on Mar 12 2026 — first high-conviction insider buy since the drawdown began; Gottesman's personal stake also up 63.8%.
• Whitefish supply tightens. 2025 Groundfish Forum projects 2026 wild-capture whitefish supply -2.2% (145K tonnes); Brisby has pre-announced 'sizeable price increases, especially in Fish' for 2026 — volume at risk in the largest category.

Four material risks — credibility collapse and the buyback cliff are the binding pair

• Guidance credibility. Met-or-beat accuracy 100% FY23 → 67% FY24 → 0% FY25 with three in-year cuts; FY26 guide has no track-record cushion and is being set by a first-time public-company CEO.
• Buyback cliff. $345M FY25 cash return against $297M FCF is 116% and is debt-funded; one more EBITDA-down year forces the buyback (and the per-share story) to stop.
• Volume decline extends. Three straight years of negative organic volume in a 'defensive' category; FY26 guide implies a fourth — begins to look like share loss to UK/German private label, not a cycle.
• Goodwill impairment. €4.6B of goodwill & intangibles against €2.7B equity; tangible book deeply negative — two more years of negative volume puts Fortenova/Iglo goodwill stacks in play.

One make-or-break quarter — Brisby's first full print against an easy -3.6% comp

• May 2026 (est). Q1 FY26 earnings — Brisby's first full quarter; organic volume vs the -3.6% Q1'25 comp is the single datapoint that matters.
• Mid-2026. Brisby's announced open-market share purchase — size and timing signal conviction after zero shares held at year-end 2025.
• July 2026. AGM director elections — dissent on Ashken (dual Comp + N&CG chair) and the Mariposa/TOMS $4M advisory-fee renewal vote.
• H2 2026. First visibility on the €200M efficiency program through 2028 — front-loaded into 2026 or back-loaded to 2028 decides the margin arc.
• Q3/Q4 2026. Interest-expense run-rate after the Nov-25 refi — stabilizing near $210M or drifting higher decides the coverage math.